© BioEcho

BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. In contrast to common bind-wash-elute procedures their proprietary EchoLUTION single-step technology avoids the use of inhibitory or harmful process reagents and does not require washing steps.

At its center for advanced rapid diagnostics (CARD), Mologic  with funding from the Bill and Melinda Gates Foundation  attained the ambitious milestone of 1pg/mL sensitivity in a visually read lateral-flow device. © Mologic

Synbio specialist Sherlock Biosciences and next-generation lateral flow testing expert Mologic Ltd have joined forces to develop a no-instrument rapid testing platform detecting virtually every infectious pathogen in low resource settings.

© pixabay/Tibor Janosi Mores

German researchers have shown that a protein protects against the development of liver fibrosis by shutting down inflammatory signalling in liver stellate cells of the liver. 

Cultured myocytes. © bit bio

Cell reprogramming specialist bit bio has expanded its management with renowned experts in the field.

© BioVersys

Swiss biotech company BioVersys AG has received a €8m grant by US-based non-profit organisation CARB-X to develop novel anti-virulence antibiotics to treat severe bacterial infections.

Amarna Therapeutics  has appointed a new Supervisory Board, led by healthcare and biotech pioneer Thomas Eldered.

MxA activates the inflammasome: Specks of ASC, one of inflammasome proteins (indicated by arrows), were observed in the lung epithelial cells of transgenic mice infected with the influenza A virus (IAV), which expressed ihuman MxA, but not in IAV-infected mice without human MxA (non-Tg) at day three post-infection. © Lee et al., Sci. Immunol. 4, eaau4643 (2019)

A team of Japanese and German researchers has found the protein that helps activate the inflammasome following viral invasion.

Diabeloop CEO Marc Julien has won the EIT Innovators Award.

Rotaviruses. © CDC

Researchers at University Lyon have found a potential repurposing application of two market-approved rotavirus vaccines.

Swiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action of a new class of antibiotics.